$100.34 +0.20 (%) Johnson & Johnson - NYSE

Mar. 27, 2015 | 04:00 PM

Partner Headlines

  1. Benzinga's M&A Chatter for Monday March 2, 2015

    Benzinga | Mar. 2, 2015 | 19:29PM EST
  2. 'Merger Monday' Lives Up To Name: From NXP Semiconductors To eBay, There's At Least $20 Billon In Total Deals

    Benzinga | Mar. 2, 2015 | 13:19PM EST
  3. Cardinal Health To Buy J&J Cardiology Device Unit

    IBD | Mar. 2, 2015 | 08:36AM EST
  4. UPDATE: Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis

    Benzinga | Mar. 2, 2015 | 07:31AM EST
  5. Medivation Tops Q4 Views On Strong Xtandi Results

    IBD | Feb. 26, 2015 | 09:56AM EST
  6. Benzinga's M&A Chatter for Wednesday February 25, 2015

    Benzinga | Feb. 25, 2015 | 21:26PM EST
  7. Pharmacyclics hits new high

    IBD | Feb. 25, 2015 | 18:51PM EST
  8. Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'

    Benzinga | Feb. 25, 2015 | 17:05PM EST
  9. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD | Feb. 25, 2015 | 14:31PM EST
  10. Johnson & Johnson Has A Potential Buyer For Its Medical Devices Unit

    GuruFocus | Feb. 24, 2015 | 10:42AM EST
  11. 3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis

    Benzinga | Feb. 23, 2015 | 13:57PM EST
  12. Morgan Stanley Analyst Sees Higher Net For Cardinal Health In Johnson & Johnson Deal

    Benzinga | Feb. 23, 2015 | 11:45AM EST
  13. Johnson & Johnson: Why Investors Should Consider This Stock for Long-Term Gains

    GuruFocus | Feb. 22, 2015 | 19:00PM EST
  14. Can These Three BioTech Companies Make It Big?

    GuruFocus | Feb. 20, 2015 | 15:22PM EST
  15. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

    Benzinga | Feb. 20, 2015 | 13:10PM EST
  16. Paul Tudor Jones Is Betting on the SPY, Should You?

    GuruFocus | Feb. 20, 2015 | 13:05PM EST
  17. 10 Stocks Institutional Investors Loved Last Quarter

    Benzinga | Feb. 20, 2015 | 11:38AM EST
  18. Sterne Agee To Investors: Caution! Boston Scientific Priced To Perfection

    Benzinga | Feb. 20, 2015 | 09:08AM EST
  19. Medtronic Q3 Earnings 2015 Exceeds Market Expectations

    GuruFocus | Feb. 19, 2015 | 17:23PM EST
  20. Retirement ETFs To Look For

    GuruFocus | Feb. 19, 2015 | 12:58PM EST
  21. Boston Scientific Closes Up 12%

    Benzinga | Feb. 18, 2015 | 16:44PM EST
  22. Boston Scientific Soars 11% After Settling Dispute With Johnson & Johnson

    Benzinga | Feb. 18, 2015 | 14:42PM EST
  23. Mid-Day Market Update: Angie's List Jumps On Upbeat Earnings; MedAssets Shares Tumble

    Benzinga | Feb. 18, 2015 | 12:51PM EST
  24. Enphase Energy (ENPH) Record-Breaking Growth, Boston Scientific (BSX) and Johnson & Johnson ...

    GuruFocus | Feb. 18, 2015 | 11:36AM EST
  25. Sterne Agree Weighs In On Boston Scientific-Johnson & Johnson Litigation Settlement

    Benzinga | Feb. 18, 2015 | 10:24AM EST
  26. Stocks Hitting 52-Week Highs

    Benzinga | Feb. 18, 2015 | 10:05AM EST
  27. Morning Market Gainers

    Benzinga | Feb. 18, 2015 | 09:38AM EST
  28. Stock Futures Show Mild Losses; Boston Scientific Bolts Higher

    IBD | Feb. 18, 2015 | 09:16AM EST
  29. Benzinga's Top #PreMarket Gainers

    Benzinga | Feb. 18, 2015 | 08:11AM EST
  30. Fast Money Halftime Report Final Trade From February 17

    Benzinga | Feb. 17, 2015 | 17:50PM EST
  31. Johnson & Johnson's Strong Product Line-Up Makes It a Stock Worth Investing In

    GuruFocus | Feb. 17, 2015 | 12:10PM EST
  32. Johnson & Johnson Aiming To Bring A New Face to Medical Research

    GuruFocus | Feb. 16, 2015 | 12:10PM EST
  33. American Firms In China Feel Anti-Foreign Sentiment Rising In The Wake Of Qualcomm Settlement

    Benzinga | Feb. 13, 2015 | 14:25PM EST
  34. Bill Ackman Thinks Valeant Is 'Incredibly Disciplined,' And Says He'd Own McDonald's If 3G Capital Was In Charge

    Benzinga | Feb. 13, 2015 | 13:06PM EST
  35. Johnson & Johnson Faces Pressure From U.S. Patent Office

    Benzinga | Feb. 13, 2015 | 11:18AM EST
  36. Johnson & Johnson Under Selling Pressure

    Benzinga | Feb. 12, 2015 | 12:01PM EST
  37. High-Quality, Low-Risk Dividend Stocks

    GuruFocus | Feb. 10, 2015 | 14:00PM EST
  38. A Robust Q4 Earnings Report From Boston Scientific

    GuruFocus | Feb. 10, 2015 | 12:58PM EST
  39. Best Stock Picks For New Investors

    GuruFocus | Feb. 9, 2015 | 15:57PM EST
  40. Model Ophelia DeVore Stood Tall In Beauty Business

    IBD | Feb. 9, 2015 | 13:36PM EST
  41. Pfizer Buying Hospira To Inject Growth Into Generics

    IBD | Feb. 5, 2015 | 17:27PM EST
  42. Mallinckrodt's Mixed Q1 Stokes Analyst Worries

    IBD | Feb. 3, 2015 | 14:09PM EST
  43. Valeant Agrees To Buy Dendreon's Provenge

    IBD | Jan. 30, 2015 | 11:39AM EST
  44. ETF Spotlight: Dividend Aristocrat Index

    Benzinga | Jan. 29, 2015 | 14:58PM EST
  45. AmerisourceBergen Hits New High On Earnings, Outlook

    IBD | Jan. 28, 2015 | 13:45PM EST
  46. Are ETFs and CEFs Good Dividend Growth Investments?

    GuruFocus | Jan. 27, 2015 | 16:15PM EST
  47. Will Johnson & Johnson Continue Soaring?

    GuruFocus | Jan. 25, 2015 | 23:16PM EST
  48. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus | Jan. 23, 2015 | 16:13PM EST
  49. Johnson & Johnson's Strong Momentum Will Continue

    GuruFocus | Jan. 22, 2015 | 17:25PM EST
  50. Morgan Stanley Analyst Sees FY15 'Trough' For Johnson & Johnson Pharma Growth

    Benzinga | Jan. 22, 2015 | 11:54AM EST
Trading Center